Cagrilintide

What Cagrilintide is

Cagrilintide is a long-acting amylin analog investigated for satiety and body-weight regulation, often in combination with GLP-1 therapies.

Cagrilintide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it gets attention because it represents the next wave of obesity pharmacology beyond GLP-1 alone.

The useful starting point is to separate the molecule itself from the internet story around it. It gets attention because it represents the next wave of obesity pharmacology beyond GLP-1 alone.

Why people keep looking it up

It gets attention because it represents the next wave of obesity pharmacology beyond GLP-1 alone.

Cagrilintide is a long-acting amylin analog investigated for satiety and body-weight regulation, often in combination with GLP-1 therapies.

Cagrilintide tends to stay in the conversation because it touches a familiar public theme: amylin analog, satiety signaling, and body weight. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Promising human metabolic data with ongoing clinical-stage status.

Human trial data exists, but it remains investigational rather than a settled approved therapy in this seed set.

Mechanistic rationale follows amylin biology and satiety signaling.

Why this page carries the current tier: Promising human metabolic data with ongoing clinical-stage status.

The current seed trail for Cagrilintide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

Combination obesity-drug narratives can move faster than approval, labeling, and long-term safety clarity.

Cagrilintide remains investigational in the contexts tracked here.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Cagrilintide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Cagrilintide is CID 171397054. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID

171397054

Formula

C194H312N54O59S2

Molecular weight

4409

InChIKey

LDERDVMBIYGIOI-IZVMHKDJSA-N

Matched synonyms include Cagrilintide, 1415456-99-3, Cagrilintide [INN], RefChem:573322, AO43BIF1U8, L-PROLINAMIDE, N-(19-CARBOXY-1-OXONONADECYL)-L-.GAMMA.-GLUTAMYL-L-LYSYL-L-CYSTEINYL-L-ASPARAGINYL-L-THREONYL-L-ALANYL-L-THREONYL-L-CYSTEINYL-L-ALANYL-L-THREONYL-L-GLUTAMINYL-L-ARGINYL-L-LEUCYL-L-ALANYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-HISTIDYL-L-SERYL-L-SERYL-L-ASPARAGINYL-L-ASPARAGINYL-L-PHENYLALANYLGLYCYL-L-PROLYL-L-ISOLEUCYL-L-LEUCYL-L-PROLYL-L-PROLYL-L-THREONYL-L-ASPARAGINYL-L-VALYLGLYCYL-L-SERYL-L-ASPARAGINYL-L-THREONYL-, CYCLIC (3->8)-DISULFIDE, L-PROLINAMIDE, N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL-L-LYSYL-L-CYSTEINYL-L-ASPARAGINYL-L-THREONYL-L-ALANYL-L-THREONYL-L-CYSTEINYL-L-ALANYL-L-THREONYL-L-GLUTAMINYL-L-ARGINYL-L-LEUCYL-L-ALANYL-L-ALPHA-GLUTAMYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-HISTIDYL-L-SERYL-L-SERYL-L-ASPARAGINYL-L-ASPARAGINYL-L-PHENYLALANYLGLYCYL-L-PROLYL-L-ISOLEUCYL-L-LEUCYL-L-PROLYL-L-PROLYL-L-THREONYL-L-ASPARAGINYL-L-VALYLGLYCYL-L-SERYL-L-ASPARAGINYL-L-THREONYL-, CYCLIC (3->8)-DISULFIDE, GTPL13768.

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Cagrilintide returns 37 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Cagrilintide returns 96 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.